Vir Biotechnology, Inc. (VIR) stock
VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3031% below fair value
$8.87−0.28 (-3.06%)
Close on Nov 19, 2026Market cap $1.50BP/E –Yield –
Vir Biotechnology cash
Cash and short-term investments held at the end of each period.
Vir Biotechnology's cash was $528.59M at Jun 30, 2026. For fiscal 2025 it was $460.94M, down 53.8% from the year before. The highest annual figure on record is $2.40B in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $460.94M | -53.8% |
| FY2024 | Dec 31, 2024 | $996.75M | -38.8% |
| FY2023 | Dec 31, 2023 | $1.63B | -32.1% |
| FY2022 | Dec 31, 2022 | $2.40B | +163.9% |
| FY2021 | Dec 31, 2021 | $909.50M | +23.4% |
| FY2020 | Dec 31, 2020 | $736.90M | +85.7% |
| FY2019 | Dec 31, 2019 | $396.92M | +260.2% |
| FY2018 | Dec 31, 2018 | $110.21M | -41.7% |
| FY2017 | Dec 31, 2017 | $188.92M | +1238.5% |
| FY2016 | Dec 31, 2016 | $14.11M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $528.59M | -11.7% |
| Q1 FY2026 | Mar 31, 2026 | $470.44M | -40.5% |
| Q4 FY2025 | Dec 31, 2025 | $460.94M | -53.8% |
| Q3 FY2025 | Sep 30, 2025 | $497.83M | -58.2% |
| Q2 FY2025 | Jun 30, 2025 | $598.75M | -58.1% |
| Q1 FY2025 | Mar 31, 2025 | $790.94M | -47.6% |
| Q4 FY2024 | Dec 31, 2024 | $996.75M | -38.8% |
| Q3 FY2024 | Sep 30, 2024 | $1.19B | -30.0% |
| Q2 FY2024 | Jun 30, 2024 | $1.43B | -24.7% |
| Q1 FY2024 | Mar 31, 2024 | $1.51B | -34.3% |
| Q4 FY2023 | Dec 31, 2023 | $1.63B | -32.1% |
| Q3 FY2023 | Sep 30, 2023 | $1.70B | -29.2% |
| Q2 FY2023 | Jun 30, 2023 | $1.90B | -17.4% |
| Q1 FY2023 | Mar 31, 2023 | $2.30B | +64.3% |
| Q4 FY2022 | Dec 31, 2022 | $2.40B | +163.9% |
| Q3 FY2022 | Sep 30, 2022 | $2.40B | +155.5% |
| Q2 FY2022 | Jun 30, 2022 | $2.30B | +162.3% |
| Q1 FY2022 | Mar 31, 2022 | $1.40B | +91.0% |
| Q4 FY2021 | Dec 31, 2021 | $909.50M | +23.4% |
| Q3 FY2021 | Sep 30, 2021 | $939.50M | +13.7% |
| Q2 FY2021 | Jun 30, 2021 | $876.70M | +58.7% |
| Q1 FY2021 | Mar 31, 2021 | $733.00M | +106.1% |
| Q4 FY2020 | Dec 31, 2020 | $736.90M | +85.7% |
| Q3 FY2020 | Sep 30, 2020 | $826.60M | +158.2% |
| Q2 FY2020 | Jun 30, 2020 | $552.40M | +584.7% |
| Q1 FY2020 | Mar 31, 2020 | $355.61M | +449.4% |
| Q4 FY2019 | Dec 31, 2019 | $396.92M | +260.2% |
| Q3 FY2019 | Sep 30, 2019 | $320.20M | +571.7% |
| Q2 FY2019 | Jun 30, 2019 | $80.68M | -57.3% |
| Q1 FY2019 | Mar 31, 2019 | $64.72M | +358.6% |
| Q4 FY2018 | Dec 31, 2018 | $110.21M | – |
| Q3 FY2018 | Sep 30, 2018 | $47.67M | – |
| Q4 FY2017 | Dec 31, 2017 | $188.92M | – |
| Q4 FY2016 | Dec 31, 2016 | $14.11M | – |
See a number that looks wrong?